3-氯-5-甲氧基苯基硼酸 | 915201-07-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-氯-5-甲氧基苯基硼酸
• 中文别名: 3-氯-5-甲氧基苯硼酸
• 英文名称: (3-chloro-5-methoxyphenyl)boronic acid
• 英文别名: 3-Chloro-5-methoxyphenylboronic acid
• CAS: 915201-07-9
• 化学式: C₇H₈BClO₃
• mdl: MFCD03095046
• 分子量: 186.403
• InChiKey: WAVZSRUGKKOQRB-UHFFFAOYSA-N

物化性质

• 熔点：
  185-189°C
• 沸点：
  359.6±52.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.91
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2931900090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H318
• 储存条件：
  存储条件为2-8°C，并需保存在惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Chloro-5-methoxyphenylboronic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-Chloro-5-methoxyphenylboronic acid
Ingredient name:
CAS number: 915201-07-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H8BClO3
Molecular weight: 186.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯-5-甲氧基苯基硼酸 在 四(三苯基膦)钯 三溴化硼 、 sodium carbonate 、 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.67h， 生成 2-(1-(4-amino-3-(3-chloro-5-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one
  参考文献：
  名称：

  NOVEL KINASE MODULATORS

  摘要：

  本发明提供了PI3K蛋白激酶调节剂，其制备方法，含有它们的药物组合物，以及使用它们进行激酶介导的疾病或紊乱的治疗、预防和/或改善的方法。

  公开号：

  US20110118257A1
• 作为产物：
  描述：

  3-氯苯甲醚 在 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer pinacol borane 、 联硼酸频那醇酯 、 4,4'-二叔丁基-2,2'-二吡啶 、 sodium periodate 、 盐酸 作用下， 以 环己烷 、 四氢呋喃 、 水 为溶剂， 反应 41.5h， 生成 3-氯-5-甲氧基苯基硼酸
  参考文献：
  名称：

  芳烃通过连续的铱催化的硼化和铜催化的偶联反应生成苯胺和芳基醚。

  摘要：

  [反应：见正文] N-烷基苯胺和N-芳基苯胺是通过铱催化的硼化和铜催化的与胺偶联的两步序列由芳烃合成的。通过芳烃硼化的相关顺序，然后与酚偶联，获得二芳基醚。特别地，通过用间位取代的芳烃起始该序列来制备3，5-二取代的芳基胺和芳基醚。

  DOI：

  10.1021/ol062902w

文献信息

• [EN] PYRIDINE SULFONAMIDES<br/>[FR] SULFONAMIDES DE PYRIDINE
  申请人：AMGEN INC

  公开号：WO2018017896A1

  公开（公告）日：2018-01-25

  The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了如规范中定义的Formula (I)的化合物，或其药用可接受的盐，这些化合物是电压门控钠通道的抑制剂，特别是Nav 1.7。这些化合物对于治疗可通过抑制钠通道治疗的疾病如疼痛障碍、咳嗽或瘙痒是有用的。还提供了含有本发明化合物的药物组合物。
• Bicyclic sulfonamide compounds as sodium channel inhibitors
  申请人：AMGEN INC.

  公开号：US09212182B2

  公开（公告）日：2015-12-15

  The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了式I的化合物及其药学上可接受的盐，这些化合物是钠通道的抑制剂，特别是Nav1.7。这些化合物对于治疗与钠通道活性相关的疾病，如疼痛障碍和瘙痒，是有用的。还提供了含有本发明化合物的药物组合物。
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：CELLCENTRIC LTD

  公开号：WO2018073586A1

  公开（公告）日：2018-04-26

  A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.

  一种化合物，其为式(I)的芳基咪唑基异噁唑（化学式(I)）或其药用可接受的盐。该化合物具有调节p300和/或CBP活性的作用，并用于治疗癌症，特别是前列腺癌。
• Catalytic Arylation of a CH Bond in Pyridine and Related Six-Membered N-Heteroarenes Using Organozinc Reagents
  作者：Isao Hyodo、Mamoru Tobisu、Naoto Chatani

  DOI：10.1002/asia.201100971

  日期：2012.6

  Despite significant advances in the catalytic direct arylation of heteroarenes, the application of this reaction to pyridines has been met with limited success. An oxidative nucleophilic arylation strategy has been developed to overcome this problem. Pyridine, pyrazine, quinolone, and related electron‐deficient N‐heteroarenes can be arylated at the most electrophilic site using the developed nickel‐catalyzed

  尽管在杂芳烃的催化直接芳基化方面取得了重大进展，但该反应在吡啶上的应用却取得了有限的成功。为了克服该问题，已经开发了一种氧化亲核芳基化策略。吡啶，吡嗪，喹诺酮和相关的电子不足的N-杂芳烃可以通过发达的镍催化反应在最亲电的位置被芳基化。该协议可作为催化直接芳基化反应的补充方法。
• Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases
  作者：Xiaohui He、Sara Da Ros、John Nelson、Xuefeng Zhu、Tao Jiang、Barun Okram、Songchun Jiang、Pierre-Yves Michellys、Maya Iskandar、Sheryll Espinola、Yong Jia、Badry Bursulaya、Andreas Kreusch、Mu-Yun Gao、Glen Spraggon、Janine Baaten、Leah Clemmer、Shelly Meeusen、David Huang、Robert Hill、Vân Nguyen-Tran、John Fathman、Bo Liu、Tove Tuntland、Perry Gordon、Thomas Hollenbeck、Kenneth Ng、Jian Shi、Laura Bordone、Hong Liu

  DOI：10.1021/acsmedchemlett.7b00258

  日期：2017.10.12

  direct inhibitors of NOD2 have not been described due to technical challenges of targeting the oligomeric protein complex. Receptor interacting protein kinase 2 (RIPK2) is an intracellular serine/threonine/tyrosine kinase, a key signaling partner, and an obligate kinase for NOD2. As such, RIPK2 represents an attractive target to probe the pathological roles of NOD2 pathway. To search for selective RIPK2

  NOD2（含有核苷酸结合的寡聚域的蛋白质2）是一种内部模式识别受体，可识别细菌肽聚糖并刺激宿主免疫反应。NOD2通路功能障碍与许多自身炎症性疾病有关。迄今为止，由于靶向寡聚蛋白复合物的技术挑战，尚未描述NOD2的直接抑制剂。受体相互作用蛋白激酶2（RIPK2）是细胞内丝氨酸/苏氨酸/酪氨酸激酶，是关键的信号传导伴侣，也是NOD2的专一性激酶。因此，RIPK2代表了一个有吸引力的靶标，以探索NOD2途径的病理作用。为了寻找选择性的RIPK2抑制剂，我们采用了虚拟文库筛选（VLS）和基于结构的设计，最终导致了有效而选择性的RIPK2抑制剂8具有优异的口服生物利用度，用于评估RIPK2在各种体外测定以及离体和体内药效学模型中的抑制作用。